Category 704 has been split into 704 (Cellular Immunotherapies: Early Phase Clinical Trials) and 705 (705 Late Phase and Commercially Available Therapies).Categories 602 and 603 have been reorganized around lineage targets rather than oncogenic mechanism, and now consist of 602 (Myeloid Oncogenesis: Basic) and 603 (Lymphoid Oncogenesis: Basic).Category 508 has been split into 508 (Bone Marrow Failure: Acquired) and 509 (Bone Marrow Failure and Cancer Predisposition Syndromes: Inherited).Category 506 (Bone Marrow Microenvironment), now encompasses interactions of the microenvironment with both normal and leukemia stem cells.The 300s Categories (Hemostasis, Thrombosis and Vascular Biology) have all been reorganized, with inclusion of basic/translational studies of thrombosis in category 301, and clinical and epidemiologic aspects of thrombotic microangiopathies and of COVID-19 in category 331, among other changes.This year, updates have been made to multiple category descriptions with significant changes as follows: Categories are updated every year to respond to submission trends and to encompass new topics. Please carefully review all descriptions before selecting a category for your abstract. A "panel" would be defined as a table or a single graphical representation of data (ie equivalent to a figure panel in a paper, not to a multi-panel figure). Abstracts may include no more than two panels of additional content.Abstracts will be limited to 3,800 characters to be accommodated on our digital platform.Your close attention is necessary to give your abstract the best chance for inclusion in the annual meeting as an oral session presentation or poster. Before you begin the process, I would like to highlight several changes in our abstract format and in abstract categories and give you more information regarding requirements for presentation of abstracts at the annual meeting. We are very pleased you are interested in submitting your research abstract to the 2022 American Society of Hematology meeting - the premier global meeting in hematology - being held in New Orleans, December 10-13, 2022. These guidelines are intended for the use of practitioners and patients who desire information about the management of operable esophageal adenocarcinoma.Call for Abstracts 64th ASH Annual Meeting and Exposition CONCLUSIONS: Chemotherapy and/or radiation regimens for esophageal cancer are still evolving with many areas of active investigation. These guidelines assess the appropriateness of various dose-fractionating schemes and target volumes. For patients found to have pathologically involved nodes (pN+) who did not receive any neoadjuvant therapy, the panel recommends that adjuvant chemoradiation is usually appropriate. For a cT2N0M0 patient with high risk features, the panel recommends that neoadjuvant chemoradiation is usually appropriate. RESULTS: For a medically operable patient with a cT3 or N+ and M0 adenocarcinoma of the esophagus or GEJ (Siewert I-II) the panel most strongly recommends neoadjuvant chemoradiation. This information was used to inform the expert panel who then rated the appropriateness of various treatments in four broadly representative clinical scenarios through a well-established consensus methodology (modified Delphi). MATERIALS AND METHODS: PRISMA systematic review methodology was employed to develop an extensive analysis of peer-reviewed phase IIR and phase III randomized controlled trials as well as meta-analyses found within the Ovid Medline, Cochrane Central and Embase databases between 2009-2019. In this systematic review, the American Radium Society (ARS) gastrointestinal expert panel convened to develop Appropriate Use Criteria (AUC) evaluating how neoadjuvant and/or adjuvant treatment regimens compared to each other, surgery alone, or definitive chemoradiation in terms of response to therapy, quality of life (QoL), and oncologic outcomes. PURPOSE: Limited guidance exists regarding the relative effectiveness of treatment options for non-metastatic, operable patients with adenocarcinoma of the esophagus or gastroesophageal junction (GEJ). Anker, CJ Dragovic, J Herman, JM Bianchi, NA Goodman, KA Jones, WE Kennedy, TJ Kumar, R Lee, P Russo, S Sharma, N Small, W Suh, WW Tchelebi, L Jabbour, SKĮxecutive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for Operable Esophageal and Gastroesophageal Junction Adenocarcinoma: Systematic Review and Guidelines.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |